Cindy Kosinski is a Product Scientist at 23andMe. In this role, she envisions and develops scientifically accurate, accessible, and engaging health reports and features to help people understand and benefit from their genetic information. Before joining 23andMe, Cindy held scientist roles at genomic technology companies, including Natera and Illumina. She earned a Ph.D. in Pharmaceutical Sciences and Pharmacogenomics from the University of California, San Francisco.
Philip Empey, UPitt
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.